Home Cart Sign in  
Chemical Structure| 908115-27-5 Chemical Structure| 908115-27-5

Structure of PF-04929113
CAS No.: 908115-27-5

Chemical Structure| 908115-27-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-04929113 is a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM.

Synonyms: SNX-5422

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PF-04929113

CAS No. :908115-27-5
Formula : C25H30F3N5O4
M.W : 521.53
SMILES Code : O=C(O[C@H]1CC[C@H](NC2=CC(N3N=C(C(F)(F)F)C4=C3CC(C)(C)CC4=O)=CC=C2C(N)=O)CC1)CN
Synonyms :
SNX-5422
MDL No. :MFCD20526334
InChI Key :AVDSOVJPJZVBTC-UHFFFAOYSA-N
Pubchem ID :44195571

Safety of PF-04929113

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PF-04929113

DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00506805 Cancer PHASE1 COMPLETED 2025-03-10 Pfizer Investigational Site, S... More >>cottsdale, Arizona, 85258, United States|Pfizer Investigational Site, Nashville, Tennessee, 37203, United States Less <<
NCT01611623 Cancer PHASE1 COMPLETED 2025-03-13 -
NCT00595686 Hematologic Neoplasms PHASE1 COMPLETED 2025-05-10 Pfizer Investigational Site, A... More >>ugusta, Georgia, 30912, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, 27599, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, 15232, United States|Pfizer Investigational Site, Nashville, Tennessee, 37232, United States Less <<
NCT01892046 Cancer PHASE1 COMPLETED 2025-07-17 Georgetown University Medical ... More >>Center, Washington, D.C., District of Columbia, 20007, United States|Georgia Regents University Cancer Center, Augusta, Georgia, 30912, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States Less <<
NCT00644072 Lymphoma|Neoplasms PHASE1 COMPLETED 2011-06-16 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT02063958 Cancer PHASE1 COMPLETED 2018-03-20 Mayo Clinic, Scottsdale, Arizo... More >>na, 85259-5499, United States|Stanford Medicine, Stanford, California, 94305, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, United States|hackensack University Medical Center, Hackensack, New Jersey, 07601, United States Less <<
NCT01848756 Cancer PHASE1|PHASE2 TERMINATED 2025-06-15 Scottsdale Healthcare, Scottsd... More >>ale, Arizona, 85258, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States Less <<
NCT01635712 Cancer PHASE1 COMPLETED 2025-02-17 UC Davis Comprehensive Cancer ... More >>Center, Sacramento, California, 95817, United States|Georgia Regents University Cancer Center, Augusta, Georgia, 30901, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37212, United States Less <<
NCT02612285 Cancer PHASE2 TERMINATED 2025-10-16 HonorHealth Research Institute... More >>, Scottsdale, Arizona, 85258, United States|Augusta University, Augusta, Georgia, 30912, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|Wexner Medical Center, Ohio State University, Columbus, Ohio, 43210, United States Less <<
NCT01851096 Cancer PHASE1 COMPLETED 2025-08-16 Georgetown University Medical ... More >>Center, Washington, District of Columbia, 20007, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.59mL

1.92mL

0.96mL

19.17mL

3.83mL

1.92mL

References

 

Historical Records

Categories